AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies
Abstract Until recently, treatment options for patients diagnosed with Acute Myeloid Leukemia (AML) were limited and predominantly relied on various combinations, dosages, or schedules of traditional chemotherapeutic agents. Patients with advanced age, relapsed/refractory disease or comorbidities we...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BMC
2024-10-01
|
| Colección: | Experimental Hematology & Oncology |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1186/s40164-024-00566-8 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|